"Zydus Lifesciences' stock jumped over 6% to a 52-week high of Rs 809.20 after announcing a proposal for a share buyback on February 9. This will be their second buyback, with the previous one in June 2022. The company will also release its December quarter results on the same day. Nuvama Institutional Equities expects a 6% rise in revenue and 17% increase in net profit.